Research Summary

Analyzed using Evidence Intelligence™

Tirzepatide with Ketogenic Diet Improves Liver Health

Last updated July 22, 2026

Key finding

CAP improved significantly with a reduction of -12.5% (p < 0.001).

The study evaluated the effects of Tirzepatide combined with either Low-Energy Ketogenic Therapy or Low-Calorie Diet on hepatic steatosis in patients with MASLD, finding significant improvements in liver parameters.

Quick read

Study at a glance

The essential study design details in one scan.

EvidenceScore™

Moderate

Study type

RCTs

Follow-up

Medium-Term (3–12 mo)

Risk of bias

Some Concerns

Save research, organize studies, and quickly find important evidence again.

Plain-language summary

What this paper says

A plain-language read of the study’s main message and where it applies.

Study focus

Clinical relevance

These findings are significant as they suggest that Tirzepatide, when paired with dietary changes, can effectively improve liver health in patients with metabolic-associated steatotic liver disease (MASLD). This could lead to better management strategies for a condition that affects a growing number of individuals worldwide.

Keep in mind

The study did not include a control group for comparison. Sample size and demographic diversity may limit generalizability. Effectiveness of interventions may vary in broader populations.

Published in

Journal Reference

Publication details and source links for this paper.

Luigi S, Biagio S, Monica M, et al. The Combination of Tirzepatide and Low-Energy Ketogenic Therapy Improves Hepatic Steatosis in Patients with MASLD. Nutrients. 2025;17(15):2409. doi:10.3390/nu17152409

View DOI View on PubMed View on PMC

Main Effects

CAP improved significantly with a reduction of -12.5% (p < 0.001).

LSM improved significantly with a reduction of -22.7% (p < 0.001).

Both groups showed significant reductions in body weight, but no significant intergroup difference (p = 0.665).

Evidence network

How this study fits

Understand where this research contributes within the broader evidence network.

Evidence Context

This study contributes evidence to Tirzepatide and BMI, Controlled attenuation parameter, HbA1c, and 1 more.

This study contributes evidence to

Intervention

Tirzepatide

Outcome

BMI

Evidence topic

HbA1c Reduction

Primary intervention

Tirzepatide

Primary outcomes

BMI
Controlled attenuation parameter
HbA1c

Evidence topics

HbA1c Reduction Weight Loss GLP-1 Receptor Agonists

Primary intervention

Tirzepatide

Primary outcomes

BMI Controlled attenuation parameter HbA1c

Evidence relationships

Intervention and outcome relationships this study adds to the evidence network.

Evidence pairs

Relationships

Evidence topics

contributes_evidence

Editorial context

Why this study matters

See why this paper is useful beyond its individual results.

Evidence network role

This section describes how the study fits into the current evidence network. It does not determine whether an intervention works on its own.

Moderate contributionModerate confidenceNetwork score: 72

Why it is useful

Contributes to 4 evidence relationships
Includes primary outcome data
Linked to 3 direct semantic evidence topics

Topic contributions

Evidence topic

Contributes evidence

Evidence topic

Contributes evidence

Evidence topic

Contributes evidence

Add related evidence to your Evidence Tracker

Save studies and evidence pages, organize your personal Evidence Tracker, and keep the research you care about in one place.

Primary evidence

Evidence relationship

GLP-1 Receptor Agonists and HbA1c

Related evidence

Evidence relationship

GLP-1 Receptor Agonists and Body Mass Index

Save evidence

Evidence topic

HbA1c Reduction

Save evidence

Core evidence

Study findings

The primary outcomes reported in this study.

BMI

Tirzepatide → BMI

Evidence Intelligence™

EvidenceScore™: Moderate; Score 69 · Based on 2 studies
ImpactScore™: 75; Positive
ConsistencyScore™: 100; consistent

Based on 2 studies

Add to Evidence Tracker

Controlled attenuation parameter

Tirzepatide → Controlled attenuation parameter

Evidence Intelligence™

EvidenceScore™: Emerging; Score 59 · Based on 1 study
ImpactScore™: 100; Very Positive
ConsistencyScore™: unclear; Not enough independent studies

Based on 1 study

Add to Evidence Tracker

HbA1c

Tirzepatide → HbA1c

Evidence Intelligence™

EvidenceScore™: 84; Strong
ImpactScore™: 96; Very Positive
ConsistencyScore™: 100; consistent

Based on 12 studies

Add to Evidence Tracker

Liver stiffness measure

Tirzepatide → Liver stiffness measure

Evidence Intelligence™

EvidenceScore™: Emerging; Score 59 · Based on 1 study
ImpactScore™: 100; Very Positive
ConsistencyScore™: unclear; Not enough independent studies

Based on 1 study

Add to Evidence Tracker

Evidence Library

Build your evidence library

Save research, organize studies, and quickly find important evidence again.

Evidence Suggest

CAP showed a significant decrease of -12.5%, indicating reduced liver fat.
LSM decreased by -22.7%, suggesting improved liver stiffness.
Both interventions resulted in similar weight loss outcomes.

Who this applies to

Adults diagnosed with metabolic-associated steatotic liver disease (MASLD).
Patients seeking weight management through dietary interventions.

Keep in Mind

Results may not apply to patients with other liver conditions.
Long-term effects of Tirzepatide and dietary interventions are not assessed.
Further studies are needed to confirm findings in larger, diverse populations.

Between the Lines

The study did not include a control group for comparison.
Sample size and demographic diversity may limit generalizability.
Effectiveness of interventions may vary in broader populations.

Evidence Library

Build your evidence library

Save research, organize studies, and quickly find important evidence again.

Connected Evidence

Explore related studies, evidence collections, and research questions.

Relationships organized using the Dediabetes Evidence Intelligence™ framework.

This study contributes to evidence on GLP-1 Receptor Agonists and HbA1c, GLP-1 Receptor Agonists and Body Mass Index.

Related evidence relationships

Explore in Evidence Explorer

This study contributes to the evidence on the following intervention-outcome relationships.

Medications

Detailed evidence

GLP-1 Receptor Agonists → HbA1c

Medications

Evidence Intelligence™

EvidenceScore™: 84; Strong
ImpactScore™: 96; Very Positive
ConsistencyScore™: 100; consistent

Based on 12 studies

View evidence

Medications

Detailed evidence

GLP-1 Receptor Agonists → Body Mass Index

Medications

Evidence Intelligence™

EvidenceScore™: Moderate; Score 69 · Based on 2 studies
ImpactScore™: 75; Positive
ConsistencyScore™: 100; consistent

Based on 2 studies

View evidence

Included in these evidence collections

Curated evidence collections and hubs this study is part of.

GLP-1 Receptor Agonists Evidence Hub

All studies on GLP-1 Receptor Agonists

12 studies

intervention_hub

Contributes to GLP-1 Receptor Agonists evidence base.

HbA1c Evidence Hub

All studies measuring HbA1c

12 studies

outcome_hub

Measures HbA1c as a key outcome.

Body Mass Index Evidence Hub

All studies measuring Body Mass Index

2 studies

outcome_hub

Measures Body Mass Index as a key outcome.

Recent Diabetes Research

Latest published studies

recency_collection

Published within the last 2 years.

Explore more in Evidence Explorer

Jump to pre-filtered views in Evidence Explorer.

All studies on Tirzepatide and HbA1c

Intervention: TirzepatideOutcome: HbA1c

12 results

All studies on Tirzepatide and BMI

Intervention: TirzepatideOutcome: BMI

2 results

All studies on Tirzepatide

Intervention: Tirzepatide

12 results

All studies measuring HbA1c

Outcome: HbA1c

12 results

All studies measuring BMI

Outcome: BMI

2 results

Questions answered by this study

Generated from the study's connected evidence using Evidence Intelligence™.

Does GLP-1 Receptor Agonists improve HbA1c?

Strong Evidence

GLP-1 Receptor Agonists appears to improve HbA1c.

ConsistencyScore™: Results are consistent across studies.

Ranked evidence signals

1
HbA1c
EvidenceScore™ Strong | EvidenceScore™ 83.9 | strong positive | ConsistencyScore™ Consistent | 1 study

Why this answer: This answer is based on 29 supporting studies with consistent results and a positive effect signal.

Limitations

Population details are unavailable.

View Full Evidence

Does GLP-1 Receptor Agonists affect body mass index?

Strong Evidence

GLP-1 Receptor Agonists may improve Body Mass Index.

ConsistencyScore™: Results are consistent across studies.

Ranked evidence signals

1
BMI
EvidenceScore™ Moderate | EvidenceScore™ 69.0 | moderate positive | ConsistencyScore™ Consistent | 1 study

Why this answer: This answer is based on 15 supporting studies with consistent results and a positive effect signal.

Limitations

Population details are unavailable.

View Full Evidence

Does Tirzepatide improve controlled attenuation parameter?

Emerging Evidence

Tirzepatide appears to improve Controlled attenuation parameter.

ConsistencyScore™: Consistency cannot yet be determined from the available evidence.

Ranked evidence signals

1
Controlled attenuation parameter
EvidenceScore™ Emerging | EvidenceScore™ 59.0 | strong positive | ConsistencyScore™ Unclear | 1 study

Why this answer: This answer is based on a single supporting study.

Limitations

Only one supporting study is available.
Consistency cannot yet be determined.
Population details are unavailable.

View Full Evidence

Does Tirzepatide improve liver stiffness measure?

Emerging Evidence

Tirzepatide appears to improve Liver stiffness measure.

ConsistencyScore™: Consistency cannot yet be determined from the available evidence.

Ranked evidence signals

1
Liver stiffness measure
EvidenceScore™ Emerging | EvidenceScore™ 59.0 | strong positive | ConsistencyScore™ Unclear | 1 study

Why this answer: This answer is based on a single supporting study.

Limitations

Only one supporting study is available.
Consistency cannot yet be determined.
Population details are unavailable.

View Full Evidence

Learn how Evidence Intelligence™ works

Next steps

Continue your research

Choose a next path through related evidence topics, Evidence Explorer views, and research summaries.

Evidence topics

Follow the topics this study contributes to.

HbA1c Reduction Evidence Hub Weight Loss Evidence Hub GLP-1 Receptor Agonists Evidence Hub

Explore in Evidence Explorer

Open broader Evidence Explorer views for this relationship.

All studies on Tirzepatide and Controlled attenuation parameter All studies on Tirzepatide and Liver stiffness measure All studies on Tirzepatide and HbA1c All studies on Tirzepatide and BMI

Related research

Read related research summaries.

Tirzepatide improves glycemic control in early-onset type 2 diabetes Tirzepatide improves cardiometabolic health in obesity.Saroglitazar improves liver health and glycemic control in type 2 diabetes Tirzepatide enhances insulin sensitivity in type 2 diabetes GLP-1 agonists reduce heart fat thickness in diabetes.

No ads. No tracking.

Focused on evidence, not advertising.

Secure & private

Your data is always protected.

Always up to date

New studies added every day.